Graves Ophthalmopathy Terminated Phase 2 Trials for Otelixizumab (DB05496)

Also known as: Thyroid-Related Eye Disease / Graves' Ophthalmopathy (GO) / Thyroid Eye Disease / Thyroid Related Eye Disease / Graves ophthalmopathy / Graves eye disease (disorder) / Thyroid eye disease with exophthalmos (disorder) / Endocrine exophthalmos (disorder) / Thyroid eye disease (disorder) / Thyroid orbitopathy (disorder) / Dysthyroid ophthalmopathy / Graves' ophthalmopathy / Endocrine ophthalmopathy / Endocrine exophthalmos / Endocrine exophthalmos NOS (disorder) / Exophthalmos endocrine

DBCOND0000969 (Graves Ophthalmopathy)Terminated2 IdentifierTitlePurposeDrugs
NCT01114503A Safety and Tolerability Study of Otelixizumab in Thyroid Eye DiseaseTreatment